KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Total Debt: 2019-2024

Historic Total Debt for Rigel Pharmaceuticals (RIGL) over the last 6 years, with Dec 2024 value amounting to $59.7 million.

  • Rigel Pharmaceuticals' Total Debt fell 0.05% to $59.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.7 million, marking a year-over-year decrease of 0.05%. This contributed to the annual value of $59.7 million for FY2024, which is 0.13% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Total Debt stood at $59.7 million for FY2024, which was up 0.13% from $59.6 million recorded in FY2023.
  • Rigel Pharmaceuticals' 5-year Total Debt high stood at $59.7 million for FY2024, and its period low was $19.8 million during FY2020.
  • Moreover, its 3-year median value for Total Debt was $59.6 million (2023), whereas its average is $52.9 million.
  • Data for Rigel Pharmaceuticals' Total Debt shows a peak YoY surged of 101.99% (in 2020) over the last 5 years.
  • Rigel Pharmaceuticals' Total Debt (Yearly) stood at $19.8 million in 2020, then rose by 0.50% to $19.9 million in 2021, then skyrocketed by 98.09% to $39.4 million in 2022, then skyrocketed by 51.09% to $59.6 million in 2023, then rose by 0.13% to $59.7 million in 2024.